Latest Healthcare Research Reports

Tag: remicade biosimilar market outlook

  • Future Outlook of the Remicade Biosimilar Market: Growth, Trends, and Emerging Opportunities Explored

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How has the remicade biosimilar market grown in recent years?

    The market size for the remicade biosimilar has seen substantial growth in recent times, expanding from $3.95 billion in 2024 to an estimated $4.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 24.9%. The significant growth during the historical period can be linked to factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, the establishment of a regulatory pathway, and pressures in healthcare costs.

    How is the remicade biosimilar market size expected to evolve during the forecast period?

    Over the next few years, the remicade biosimilar market is projected to witness remarkable growth. By 2029, it would attain a value of $11.07 billion, escalating at a Compound Annual Growth Rate (CAGR) of 22.4%. The swift growth during the forecast period can be accredited to the expiration of patents, an increase in demand for affordable treatments, the development of biosimilar pipelines, the consolidation of the market, and reimbursement policies. Noteworthy trends to watch for within this period comprise changes in doctor prescription habits, the management of the biosimilar life cycle, naming conventions for biosimilars, interchangeability of biosimilars, and evidence from the real world regarding biosimilars.

    Get your remicade biosimilar market report here!

    https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

    Which key drivers are propelling the remicade biosimilar market’s growth?

    The escalation in the prevalence of autoimmune diseases is anticipated to drive the expansion of the remicade biosimilar market. Autoimmune diseases constitute disorders where the immune system erroneously harms the body’s tissues and organs. Remicade biosimilars offer an efficient therapeutic solution for alleviating symptoms and curbing inflammation linked to these conditions. For example, in July 2023, Public Health Scotland, a Scottish organization, revealed that in 2022 the percentage of newly diagnosed patients suffering from multiple sclerosis (MS) leaped to 87.2%, an increase from 85.7% in 2020. A total of 491 fresh cases were documented, accumulating the total figure to 6,359 in 2022. Thus, the escalating prevalence of autoimmune diseases is fuelling the expansion of the remicade biosimilar market.

    What are the market segments in the remicade biosimilar industry?

    The remicade biosimilar market covered in this report is segmented –

    1) By Type: 100mg/10ml, 500mg/50ml

    2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

    3) By Application: Blood Disorders, Oncology Diseases

    Subsegments:

    1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

    2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

    Which leading companies are shaping the growth of the remicade biosimilar market?

    Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

    What key trends are currently impacting the remicade biosimilar market’s development?

    Product innovation is emerging as a significant trend in the Remicade biosimilar market. Big players in the Remicade biosimilar market are creating inventive products to maintain their standing. For instance, in January 2023, U.S.-based biotechnology firm Amgen Inc. rolled out Amjevita, a biosimilar equivalent of AbbVie’s Humira, in the U.S, engineered to be as secure and effective as the authentic drug. Amjevita, being Humira’s first biosimilar, is set to vie with Humira for market share. This biological medicine treats various autoimmune illnesses, including rheumatoid arthritis and Crohn’s disease. It ranks among the highest-priced drugs globally, contributing billions in annual sales for AbbVie. Nonetheless, Amjevita’s cost is expected to be significantly lower, offering monetary savings and increased treatment options for patients.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11952

    Which geographic areas are influencing the growth of the remicade biosimilar market?

    Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Biologics Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery

    https://www.thebusinessresearchcompany.com/report/biologics-market

    Pharmaceutical API Manufacturing Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

    Agricultural Biologics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/agricultural-biologics-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Key Drivers and Opportunities in the Remicade Biosimilar Market: Insights into Trends and Growth

    Key Drivers and Opportunities in the Remicade Biosimilar Market: Insights into Trends and Growth

    What Long-Term Growth Rate is Expected for the Remicade Biosimilar Market Between 2025 and 2034?
    The remicade biosimilar market has witnessed exponential growth in recent years. It is expected to rise from $3.95 billion in 2024 to $4.93 billion in 2025, with a remarkable CAGR of 24.9%. The past growth is attributed to the introduction of remicade (infliximab), advancements in biotechnology, patent expirations of biologics, the establishment of regulatory pathways, and pressures related to healthcare costs.

    The remicade biosimilar market is expected to grow exponentially, reaching $11.07 billion by 2029 at a CAGR of 22.4%. This expansion is fueled by patent expirations, rising demand for cost-effective treatments, a growing biosimilar pipeline, evolving reimbursement policies, and market consolidation. Key trends include physician prescribing behaviors, biosimilar lifecycle management, naming conventions, interchangeability, and real-world evidence collection.

    Which Factors Are Enhancing the Growth of the remicade biosimilar Market?
    The rise in autoimmune disease cases is expected to propel the growth of the remicade biosimilar market in the future. Autoimmune diseases are conditions where the immune system mistakenly attacks and damages the body’s tissues and organs. Remicade biosimilars are utilized in treating autoimmune diseases, offering effective therapeutic options to manage symptoms and reduce associated inflammation. For instance, in July 2023, data from Public Health Scotland, a Scotland-based national organization, revealed that in 2022, newly diagnosed patients with multiple sclerosis (MS) rose to 87.2%, up from 85.7% in 2020, with 491 new cases reported, totaling 6,359 in 2022. Therefore, the increase in autoimmune disease incidence is driving the growth of the remicade biosimilar market.

    Explore Comprehensive Insights Into The Global Remicade Biosimilar Market With A Free Sample Report:
    https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

    What Are the Key Firms That Are Driving Transformation in the Remicade Biosimilar Market?
    Major companies operating in the remicade biosimilar market include:
    • Novartis AG

    • Amgen Inc

    • Viatris Inc.

    • Teva Pharmaceutical Industries Ltd.

    • Biogen Inc.

    What Current Trends in the Remicade Biosimilar Market Should Industry Players Pay Attention To?
    Product innovation is also a significant trend in the Remicade biosimilar market. Leading companies in this sector are developing new biosimilar products to strengthen their market position. For example, in January 2023, Amgen Inc., a US-based biotechnology company, introduced Amjevita, a biosimilar alternative to AbbVie’s Humira, in the US market. Designed to be as safe and effective as Humira, Amjevita is the first biosimilar of its kind and is anticipated to compete directly with Humira in terms of market share. It is used for treating autoimmune disorders like rheumatoid arthritis and Crohn’s disease. As Humira is one of the most expensive drugs globally, Amjevita is expected to be a more affordable alternative while offering patients more treatment options.

    Secure Your Global Remicade Biosimilar Market Report Now for Fast and Efficient Delivery!
    https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

    What Are the Main Segments of the Remicade Biosimilar Market, and How Are They Evolving?
    The remicade biosimilar market covered in this report is segmented –

    1) By Type: 100mg/10ml, 500mg/50ml
    2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
    3) By Application: Blood Disorders, Oncology Diseases

    Subsegments:
    1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes
    2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

    What Regions Are Driving Expansion in the Remicade Biosimilar Market?
    Europe  was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Does the Definition of the Remicade Biosimilar Market Include?
    Remicade biosimilar refers to a biological drug like Remicade used to treat certain autoimmune diseases in adults and children. It treats autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

    Browse Through More Similar Reports By The Business Research Company:

    Biologics Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery
    https://www.thebusinessresearchcompany.com/report/biologics-market

    Pharmaceutical API Manufacturing Global Market Report 2024
    https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

    Agricultural Biologics Global Market Report 2024
    https://www.thebusinessresearchcompany.com/report/agricultural-biologics-global-market-report

    About The Business Research Company:
    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:
    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • 2024-2033 Remicade Biosimilar Market: Key Insights on Growth Opportunities

    2024-2033 Remicade Biosimilar Market: Key Insights on Growth Opportunities

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What is the Expected Growth Trajectory for the Remicade Biosimilar Market by 2033?

    In recent times, the size of the remicade biosimilar market has seen a significant upsurge. It is estimated to show an expansion from $3.2 billion in 2023 to $3.99 billion in 2024, with a compound annual growth rate (CAGR) of 24.4%. Factors such as the launch of remicade (infliximab), advances in biotechnology, expiration of biologics patents, the establishment of regulatory pathways and pressures on healthcare costs have contributed to the historical period growth.

    The market size of Remicade biosimilars is expected to witness remarkable growth over the next few years and is predicted to reach $9.1 billion by 2028, growing at a compound annual growth rate (CAGR) of 22.9%. This projected growth during the forecast period is driven by factors such as patent expirations, increasing demand for affordable treatments, development of biosimilar pipelines, reimbursement policies, and market consolidation. Key trends during this period include changes in physician prescription habits, the management of the biosimilar lifecycle, naming conventions for biosimilars, interchangeable biosimilars, and real-world evidence of biosimilar efficacy.

    Claim Your Free Sample of the Global Remicade Biosimilar Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

    What Factors Are Leading to Growth in the remicade biosimilar Market?

    The remicade biosimilar market’s growth is predicted to be boosted due to an escalation in the occurrence of autoimmune diseases. These diseases, caused by the immune system erroneously damaging the body’s tissues and organs, are effectively treated with remicade biosimilars. They provide a reliable therapy choice to manage inflammation and other symptoms related to these diseases. For example, based on data from the City University of London in October 2021, 7% of the UK population, amounting to 4 million citizens, were diagnosed with autoimmune diseases in the same year. Moreover, upwards of 80 such diseases were discovered with an annually increasing prevalence rate of 3–9%. In correspondence, the Cleveland Clinic reported in July 2021, that 1 out of every 15 individuals in the US had autoimmune diseases, with conditions like Crohn’s disease and ulcerative colitis affecting 1.4 million and lupus affecting 1 million people in 2021. Consequently, the escalating incidence of autoimmune diseases represents a major catalyst for the future expansion of the Remicade biosimilar market.

    Which Segments Play a Key Role in Understanding the Remicade Biosimilar Market?

    1) By Type: 100mg/10ml, 500mg/50ml

    2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

    3) By Application: Blood Disorders, Oncology Diseases

    What Trends Are Emerging as Game-Changers in the Remicade Biosimilar Market?

    Product innovation is becoming a crucial trend within the Remicade biosimilar market. Top firms in the market, such as Amgen Inc., a biotechnology company from the US, are creating groundbreaking products to retain their market standing. For instance, in January 2023, Amgen launched Amjevita, the first biosimilar to Humira, an existing product of AbbVie. The launch was carried out in the United States, with the aim of ensuring it is as effective and safe as the original drug. Amjevita will compete with Humira for market share and it’s intended to treat a range of autoimmune diseases, including rheumatoid arthritis and Crohn’s disease, similar to its counterpart. Humira is one of the priciest drugs globally, bringing in billions of dollars for AbbVie annually. However, Amjevita is anticipated to have a significantly lower cost, which could result in money savings and provide patients with a wider array of treatment options.

    Order Now for Fast Delivery of Your Remicade Biosimilar Market Report!

    https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

    Which Regions Are Setting the Pace for Remicade Biosimilar Market Growth?

    Europe was the largest region in the remicade biosimilar market in 2023. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Remicade Biosimilar Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the remicade biosimilar market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Remicade Biosimilar Market Include

    1. Remicade Biosimilar Market Executive Summary

    2. Remicade Biosimilar Market Segments

    3. Remicade Biosimilar Market Size And Template Market Growth Rate

    4. Key Remicade Biosimilar Market Trends

    5. Major Remicade Biosimilar Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Remicade Biosimilar Market

    26. Top Remicade Biosimilar Companies

    27. Remicade Biosimilar Market Opportunities And Strategies

    28. Remicade Biosimilar Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Insulin biosimilars Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report

    Biosimilar Therapeutic Peptides Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

    Oncology Biosimilars Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Key Takeaways From The Global Remicade Biosimilar Market Forecast 2024

    Key Takeaways From The Global Remicade Biosimilar Market Forecast 2024

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    As per The Business Research Company’s Remicade Biosimilar Global Market Report 2024, the remicade biosimilar market is expected to show significant growth in the forecast period.

    The remicade biosimilar market has witnessed exponential growth in recent years, with promising projections for the future. Let’s delve into the factors fueling this growth and the trends shaping the market landscape.

    Exponential Growth Trajectory

    • The market size surged from $3.2 billion in 2023 to $3.99 billion in 2024, exhibiting a remarkable compound annual growth rate (CAGR) of 24.4%.
    • Projections indicate further growth, with expectations to reach $9.1 billion by 2028, boasting a CAGR of 22.9%.

    Factors Driving Growth

    Introduction of Remicade and Biotechnological Advancements

    • The introduction of remicade (infliximab) and advancements in biotechnology have played pivotal roles in market expansion.
    • Remicade biosimilars offer effective therapeutic options for managing symptoms and reducing inflammation associated with autoimmune diseases.

    Biologics Patent Expiry and Regulatory Pathway Establishment

    • Patent expirations and established regulatory pathways have facilitated the development and commercialization of biosimilars, driving market growth.
    • Regulatory reforms have streamlined approval processes, fostering competition and affordability in the market.

    Healthcare Cost Pressures

    • Rising healthcare costs have spurred the demand for cost-effective therapies, propelling the adoption of remicade biosimilars.
    • Biosimilars present a viable alternative to expensive biologic drugs, addressing affordability concerns and widening patient access.

    View More On The Remicade Biosimilar Market Report 2024 – https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

    Key Trends and Market Dynamics

    Surge in Autoimmune Diseases

    • The escalating incidence of autoimmune diseases worldwide, characterized by immune system dysregulation, is a significant driver of market growth.
    • Reports indicate a substantial rise in autoimmune disorders, driving the demand for remicade biosimilars as effective treatment options.

    Innovative Biosimilar Launches

    • Product innovation emerges as a prominent trend, with companies focusing on developing novel biosimilar formulations to gain competitive advantage.
    • Launches like Amjevita by Amgen Inc. demonstrate efforts to offer safer, cost-effective alternatives to existing biologics, fostering market competition.

    Market Consolidation and Strategic Acquisitions

    • Strategic acquisitions, such as Samsung Biologics’ acquisition of Samsung Bioepis Co. Ltd., bolster market players’ capabilities and global presence.
    • Consolidation efforts aim to enhance manufacturing capacities and diversify biosimilar portfolios, catering to evolving market demands.

    Segmentation and Regional Insights

    Segmentation Overview

    • The remicade biosimilar market is segmented by type, disease indication, and application, catering to diverse patient needs and therapeutic requirements.
    • Segments include variations in dosage forms, disease indications, and therapeutic applications, reflecting the market’s versatility.

    Regional Dominance

    • Europe emerged as the largest region in the remicade biosimilar market in 2023, underscoring the region’s significant market share and robust growth potential.
    • Regional dynamics influence market trends and demand patterns, shaping strategic initiatives and market penetration strategies.

    Conclusion: Navigating the Future

    The remicade biosimilar market presents lucrative opportunities amidst evolving healthcare landscapes and escalating demand for affordable, high-quality treatments. As market players innovate and expand their portfolios, patients stand to benefit from enhanced access to safe, effective therapies. With a focus on addressing unmet medical needs and optimizing healthcare outcomes, the journey ahead promises exciting developments and transformative advancements in the realm of biosimilar therapeutics.

    Request A Sample Of The Global Remicade Biosimilar Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=11952&type=smp